Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tim Demuth

Showing results (11-20 of 22) with videos related to

Pageof 3
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 11, 2011
MK-1775, a potent Wee1 inhibitor, synergizes with gemcitabine to achieve tumor regressions, selectively in p53-deficient pancreatic cancer xenograftsN V Rajeshkumar, Elizabeth De Oliveira, Niki Ottenhof, et al.
Molecular Cancer Therapeutics|April 5, 2007
MAP-ing glioma invasion: mitogen-activated protein kinase kinase 3 and p38 drive glioma invasion and progression and predict patient survivalTim Demuth, Linsey B Reavie, Jessica L Rennert, et al.
The Journal of Experimental Medicine|February 22, 2012
Gamma secretase inhibition promotes hypoxic necrosis in mouse pancreatic ductal adenocarcinomaNatalie Cook, Kristopher K Frese, Tashinga E Bapiro, et al.
Blood|January 24, 2012
RNAi screening of the kinome with cytarabine in leukemiasRaoul Tibes, James M Bogenberger, Leena Chaudhuri, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 10, 2011
Phase I trial of MK-0752 in children with refractory CNS malignancies: a pediatric brain tumor consortium studyMaryam Fouladi, Clinton F Stewart, James Olson, et al.
British Journal of Haematology|April 12, 2013
A phase II study of Givinostat in combination with hydroxycarbamide in patients with polycythaemia vera unresponsive to hydroxycarbamide monotherapyGuido Finazzi, Alessandro M Vannucchi, Vincenzo Martinelli, et al.
Cancer Research|November 12, 2009
De novo discovery of a gamma-secretase inhibitor response signature using a novel in vivo breast tumor modelJames W Watters, Chun Cheng, Pradip K Majumder, et al.
BMC Genomics|January 31, 2008
Glioma cells on the run - the migratory transcriptome of 10 human glioma cell linesTim Demuth, Jessica L Rennert, Dominique B Hoelzinger, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 8, 2016
Phase I Study Evaluating WEE1 Inhibitor AZD1775 As Monotherapy and in Combination With Gemcitabine, Cisplatin, or Carboplatin in Patients With Advanced Solid TumorsSuzanne Leijen, Robin M J M van Geel, Anna C Pavlick, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 2, 2012
Phase I pharmacologic and pharmacodynamic study of the gamma secretase (Notch) inhibitor MK-0752 in adult patients with advanced solid tumorsIan Krop, Tim Demuth, Tina Guthrie, et al.
Pageof 3

Showing results (11-20 of 22) with videos related to

Sort By:
Pageof 3
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 11, 2011
MK-1775, a potent Wee1 inhibitor, synergizes with gemcitabine to achieve tumor regressions, selectively in p53-deficient pancreatic cancer xenograftsN V Rajeshkumar, Elizabeth De Oliveira, Niki Ottenhof, et al.
Molecular Cancer Therapeutics|April 5, 2007
MAP-ing glioma invasion: mitogen-activated protein kinase kinase 3 and p38 drive glioma invasion and progression and predict patient survivalTim Demuth, Linsey B Reavie, Jessica L Rennert, et al.
The Journal of Experimental Medicine|February 22, 2012
Gamma secretase inhibition promotes hypoxic necrosis in mouse pancreatic ductal adenocarcinomaNatalie Cook, Kristopher K Frese, Tashinga E Bapiro, et al.
Blood|January 24, 2012
RNAi screening of the kinome with cytarabine in leukemiasRaoul Tibes, James M Bogenberger, Leena Chaudhuri, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 10, 2011
Phase I trial of MK-0752 in children with refractory CNS malignancies: a pediatric brain tumor consortium studyMaryam Fouladi, Clinton F Stewart, James Olson, et al.
British Journal of Haematology|April 12, 2013
A phase II study of Givinostat in combination with hydroxycarbamide in patients with polycythaemia vera unresponsive to hydroxycarbamide monotherapyGuido Finazzi, Alessandro M Vannucchi, Vincenzo Martinelli, et al.
Cancer Research|November 12, 2009
De novo discovery of a gamma-secretase inhibitor response signature using a novel in vivo breast tumor modelJames W Watters, Chun Cheng, Pradip K Majumder, et al.
BMC Genomics|January 31, 2008
Glioma cells on the run - the migratory transcriptome of 10 human glioma cell linesTim Demuth, Jessica L Rennert, Dominique B Hoelzinger, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 8, 2016
Phase I Study Evaluating WEE1 Inhibitor AZD1775 As Monotherapy and in Combination With Gemcitabine, Cisplatin, or Carboplatin in Patients With Advanced Solid TumorsSuzanne Leijen, Robin M J M van Geel, Anna C Pavlick, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 2, 2012
Phase I pharmacologic and pharmacodynamic study of the gamma secretase (Notch) inhibitor MK-0752 in adult patients with advanced solid tumorsIan Krop, Tim Demuth, Tina Guthrie, et al.
Pageof 3